Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Oncology Institute Inc (TOI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/29/2025: TOI (3-star) is a STRONG-BUY. BUY since 9 days. Profits (-0.82%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 302.64% | Avg. Invested days 27 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 346.51M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.04 | 52 Weeks Range 0.13 - 4.04 | Updated Date 07/29/2025 |
52 Weeks Range 0.13 - 4.04 | Updated Date 07/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.96% | Operating Margin (TTM) -9.49% |
Management Effectiveness
Return on Assets (TTM) -17.66% | Return on Equity (TTM) -277.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 409081788 | Price to Sales(TTM) 0.86 |
Enterprise Value 409081788 | Price to Sales(TTM) 0.86 | ||
Enterprise Value to Revenue 1.01 | Enterprise Value to EBITDA -1.87 | Shares Outstanding 91913696 | Shares Floating 66848843 |
Shares Outstanding 91913696 | Shares Floating 66848843 | ||
Percent Insiders 9.33 | Percent Institutions 34.72 |
Upturn AI SWOT
Oncology Institute Inc
Company Overview
History and Background
The Oncology Institute, Inc. (TOI) was founded to provide comprehensive cancer care services through community-based cancer centers. It focuses on value-based care and aims to improve patient outcomes while reducing healthcare costs. The company has grown through acquisitions and expansions of its service offerings.
Core Business Areas
- Comprehensive Cancer Care Services: Includes medical oncology, radiation oncology, surgical oncology, and hematology services.
- Value-Based Care: Focuses on improving patient outcomes and reducing costs through coordinated care and innovative treatment approaches.
- Research and Clinical Trials: Engages in research and clinical trials to advance cancer treatment and patient care.
Leadership and Structure
The Oncology Institute is led by a management team with experience in healthcare administration and oncology. Details on specific individuals and organizational charts can be found in company reports and filings.
Top Products and Market Share
Key Offerings
- Medical Oncology: Provides chemotherapy, immunotherapy, and targeted therapy for cancer patients. Market share data is difficult to pinpoint precisely due to varying regional factors. Competitors: McKesson, Cardinal Health, AmerisourceBergen.
- Radiation Oncology: Offers radiation therapy services using advanced technologies. Market share data is difficult to pinpoint precisely due to varying regional factors. Competitors: Varian Medical Systems, Accuray Incorporated.
- Hematology: Specializes in the diagnosis and treatment of blood disorders. Market share data is difficult to pinpoint precisely due to varying regional factors. Competitors: McKesson, Cardinal Health, AmerisourceBergen.
Market Dynamics
Industry Overview
The oncology market is experiencing growth due to an aging population, advancements in cancer treatment, and increased awareness. Value-based care models are gaining traction as healthcare providers seek to improve patient outcomes and reduce costs.
Positioning
The Oncology Institute positions itself as a leading provider of comprehensive, value-based cancer care in community settings. Its competitive advantages include its integrated care model, focus on patient outcomes, and participation in clinical trials.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. The Oncology Institute aims to capture a significant portion of this market through its expansion strategy and focus on value-based care.
Upturn SWOT Analysis
Strengths
- Comprehensive cancer care services
- Value-based care model
- Community-based cancer centers
- Participation in clinical trials
- Experienced management team
Weaknesses
- High dependence on reimbursement rates
- Competition from larger healthcare providers
- Integration challenges from acquisitions
- Profitability Challenges
Opportunities
- Expansion into new geographic markets
- Increased adoption of value-based care
- Partnerships with hospitals and payers
- Development of new cancer treatments
Threats
- Changes in healthcare regulations
- Rising costs of cancer treatment
- Competition from other oncology providers
- Drug pricing pressures
Competitors and Market Share
Key Competitors
- USON
- CRH
Competitive Landscape
TOI faces competition from other cancer care providers, hospital systems, and pharmaceutical companies. Its advantages include its value-based care model and community-based approach. Challenges include competing with larger, more established players. The market share numbers provided are estimates due to lack of complete market data.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is assessed by analyzing past revenue and earnings data from financial statements.
Future Projections: Future growth projections are based on analyst estimates. Review research reports from investment firms for forecasts.
Recent Initiatives: Recent initiatives may include acquisitions, partnerships, and new program launches, as detailed in company press releases and investor presentations.
Summary
The Oncology Institute aims to provide comprehensive cancer care in accessible community settings and a value based model. They face intense competition and potential regulatory challenges. Successful integration of acquired practices and proving the scalability of the value-based model are critical to the companyu2019s growth. Further expansion into new markets and managing costs while maintaining quality are key for future success. Further, TOI's financial health remains a concern.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Market Research Reports
- Analyst Estimates
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data are estimates. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oncology Institute Inc
Exchange NASDAQ | Headquaters Cerritos, CA, United States | ||
IPO Launch date 2021-11-15 | CEO & Executive Director Dr. Daniel Virnich FACHE, M.B.A., M.D. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 825 | Website https://theoncologyinstitute.com |
Full time employees 825 | Website https://theoncologyinstitute.com | ||
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.